Objective: Silicone usage for cosmetic enhancement is common, although it is not approved by the U.S. Food and Drug Administration. Granulomatous inflammation leading to hypercalcemia is a rare complication. We present a case of non-parathyroid hormone (PTH), calcitriolmediated hypercalcemia in a woman with a history of cosmetic injections.
D was 47 pg/mL, and 1,25-dihydroxyvitamin D was 121 pg/mL. Angiotensin-converting enzyme level was 80 U/ mL. A diagnosis of granulomatous inflammation resulting in calcitriol-mediated, PTH-independent hypercalcemia was entertained.
Conclusion: Silicone-induced hypercalcemia should be thought of in those with prior cosmetic injections. Tissue biopsy confirms the diagnosis, which is often delayed. We reviewed 19 cases with silicone usage and variable levels of hypercalcemia. Renal injury was common. One death was reported. Glucocorticoids, calcium restriction, and hydration have been used to treat calcitriol-mediated hypercalcemia but are not curative. Ketoconazole and bisphosphonates have been used with variable success. Surgical excision tends to be ineffective due to silicone migration. The treatment of this disorder is difficult and often ineffective. (AACE Clinical Case Rep. 2019;5:e119-e123)
INTRODUCTION
Various forms of cosmetic fillers are in use today, including collagen, silicone, and polymethymethacrylate (PMMA). Of these, collagen, hyaluronic acid, and PMMA are approved by the U.S. Food and Drug Administration (FDA). Silicone, on the other hand, is not FDA approved for any anatomic site (1) . Silicone oil is approved for usage in retinal surgeries (2) . Silicone use for cosmetic injections is in abundance in the U.S., mainly due to low costs, undemanding equipment, and quick postprocedure recovery. In 2013, 12,000 procedures involving buttocks and 313,000 involving breasts were performed (3). True granuloma formation post cosmetic procedure is a rare phenomenon, reported in 0.02 to 1% of cases. Changes in composition, irregularities, and contamination in the filler products may be responsible for granulomatous inflammation (4) . Even more rare is the occurrence of hypercalcemia due to calcitriol production from the granuloma. Only 19 such cases due to silicone use in adults have been reported.
CASE REPORT
A 48-year-old Hispanic female with a medical history of hypertension, dyslipidemia, chronic kidney disease, and multiple kidney stones was referred to the endocrinology clinic for evaluation of severe hypercalcemia by her primary care physician. She denied any fatigue, loss of appetite, or changes in weight at the time. She denied any nausea, abdominal pain, or constipation. She had developed severe hypercalcemia (serum calcium >15 mg/dL) around 6 years previous. On further questioning, she revealed that over the last few years she had noted the development of an intermittent rash over her right buttock and lateral thigh area. Ten years previous, she had received a cosmetic injection to her buttocks at home. Her medications included vitamins, losartan, and simvastatin. Her vitals were within normal limits. Her physical examination was otherwise unremarkable. Her prior laboratory tests revealed a low-normal parathyroid hormone (PTH), normal 25-hydroxyvitamin D, elevated 1,25-dihydroxyvitamin D, and hypercalciuria. Repeat laboratory tests revealed a total serum calcium of 11.3 mg/dL, serum albumin 2 mg/dL, corrected serum calcium 12.9 mg/dL, normal PTH, and 24-hour urinary calcium with a PTH-related peptide of 18 pmol/L (normal, <2 pmol/L). Serum and urine electrophoresis were normal. Serum 25-hydroxyvitamin D levels were normal, and 1,25-dihydroxyvitamin D levels were elevated at 121 pg/ mL (normal, 19 to 79 pg/mL). Serum angiotensin-convert-ing enzyme (ACE) level was normal as well. Her complete blood count and sodium, potassium, liver functions, and creatinine were normal. Computed tomography (CT) scan of the lungs did not show any suspicious lesions for sarcoid, tuberculosis, or berylliosis, nor did the patient give history of such an exposure. A positron emission tomography (PET)/CT scan showed metabolic activity in the buttocks and thighs bilaterally, corresponding to the injection sites (Fig. 1 ). It did not reveal any suspicious lymph nodes to prompt us to add lymphoma to the differential. The diagnosis of granulomatous inflammation resulting in calcitriol-mediated, PTH-independent hypercalcemia was considered based on the biochemical and imaging data as well as her medical history.
DISCUSSION
In 1948, Frisch et al (5) described silicone as inert. Since then, the interest in and use of silicone for cosmetic purpose rose steadily. Its exact long-term effects remain unknown. Liquid injectable silicone use was banned by the FDA in 1991. Despite that, its use continues, especially in the form of illicit injections used as fillers for cosmetic purposes.
The earliest evidence of silicone causing the formation of a foreign body granuloma was reported in 1964 by Winer et al (6) . They described three biopsy-proven cases of granuloma formation following silicone injection as "siliconomas" and advised against its use. The pathophysiology behind this is thought to be an autoimmune reaction to silicone that essentially acts as a foreign body, causing macrophage activation and release of various cytokines, such as tumor necrosis factor-alpha and interleukins 1 and 6 (7) . The mechanism is similar to granuloma formation in sarcoidosis and exhibits similar histologic morphology (8). These macrophages exhibit 1-alpha hydroxylase activity, which in turn converts the inactive metabolite of vitamin D (25-hydroxyvitamin D3) to the active form (1,25-dihydroxyvitamin D3). This process is unregulated and increases the calcium absorption in the gut, causing hypercalcemia. It is essential to rule out sarcoidosis-related excessive calcitriol formation before proceeding to other diagnoses, which was done in our case with negative chest imaging and normal ACE levels. Tuberculosis and berylliosis-related granulomas should also be excluded, as was done in our case.
The first case that actually reported a possible concomitant occurrence of hypercalcemia and silicone inflammation was described by Pearl et al (9) in 1978, involving a transsexual patient who received multiple injections of a filler that possibly contained silicone along with steroid injections for body contouring. However, in that case, the patient had developed cellulitis and swelling at the injection sites and was being treated with antibiotics.
A recent systematic review by Tachamo et al (10) looked at 23 cases. The mean age of diagnosis was at 49.83 ± 14.7 years, with female preponderance and the time frame of diagnosis of hypercalcemia averaging around 7.96 ± 7 years after procedure. Injections to breasts were the most common in their study group, followed by buttocks (10) . Another study by Rapaport (11) analyzed 50 cases of silicone injections. They were seen for various problems occurring 2 to 25 years postinjections. They described cases with chronic cellulitis, nodule formation, shifting of material within the body, and even one suspicious case of sarcoid in the lung thought to be caused by silicone (11) . As such cases are rare, the exact number of people developing hypercalcemia post-silicone-related granuloma formation remains unknown. Kozeny et al (12) suggested that the number of granulomas formed, their mass, and their immunologic activity play a role along with various genetic and environmental factors. The exact cause, however, remains unknown.
Routine imaging in the form of CT scanning or magnetic resonance imaging may not always reveal a granuloma. PET scanning has been used with success to identify inflammation and granuloma formation. These changes are often noted at the site of injections and can even show displaced silicone beyond the intended injection site (13) . In our case, imaging showed tracking along the thigh, which corresponded to the history of rash likely due to spread of the injected material. To further establish the diagnosis, histology is of benefit. Histology is expected to reveal a cystic and macrophage-laden granuloma with microcyst formation in the dermis layer with vacuoles,
giving it a "Swiss cheese" appearance (14) .
The management of the hypercalcemia is with standard hydration with corticosteroids (15) . Glucocorticoids usually reduce serum calcium levels by decreasing calcitriol production by the activated mononuclear cells. If needed, bisphosphonates and denosumab are also used. The role of calcimimetics is questionable, as these act on the calcium-sensing receptor on the parathyroid gland, which concomitantly lowers the PTH, serum calcium, and phosphorous levels. In our case, the hypercalcemia was non-PTH mediated. Similarly, calcitonin acts by antagonizing the effects of PTH and would be less useful. Various other modalities of treatment have been mentioned, which have not been proven to be beneficial in every case. Adams et al (16) discussed the use of chloroquine to control calcium. Ketoconazole is noted to have anti-1-alpha hydroxylase activity and has shown some benefit in sarcoidosis and hence also with silicone granulomas (17) . Pasternack et al (18) described the use of etanercept, a monoclonal antibody, to treat two cases of resistant hypercalcemia due to silicone injections with success. Surgical resection has been tried but has not shown success, as the injected material can migrate with time.
It has been seen that hypercalcemia once controlled could recur and lead to renal failure. This has been the most common complication reported, with possible dialysis dependence (19) . A systematic review by Tachamo et al (10) found two reported cases of deaths. One was from recurrent, uncontrollable hypercalcemia leading to renal failure. The other case reported the development of urosepsis that led to the patient's death. The authors reported 23 eligible cases with silicone, PMMA, and paraffin oil injections. The mean interval from the time of injection to the development of hypercalcemia was 7 years. Two deaths occurred and 2 other patients had unsuccessful surgical attempts. The remaining 19 (82.6%) cases were medically treated (19) . Granulomatous disease should be considered in the differential diagnosis of patients with prior cosmetic procedures who present with non-PTH-mediated hypercalcemia. The onset of the hypercalcemia may be delayed and the diagnosis frequently overlooked. Although the disease seldom leads to death, it is often difficult to treat, as surgery has a limited role and pharmacologic treatment is noncurative. A thorough history inquiring about prior cosmetic procedures is the key to diagnosis. Table 1 summarizes cases of hypercalcemia due to silicone injection-related granuloma formation, and Table 2 summarizes rare causes of hypercalcemia associated with elevated vitamin D levels.
CONCLUSION
Silicone-induced hypercalcemia should be considered in the differential of those with prior cosmetic injections. Hypercalcemia often presents many years following the injection of silicone, methacrylate, or paraffin. A tissue biopsy confirms the diagnosis, which is often delayed. Hypercalcemia could be severe and even life threatening. Renal injury is common, and two deaths have been reported. Glucocorticoids, calcium restriction, and hydration can treat calcitriol-mediated hypercalcemia, but they Abbreviations: F = female; HD = hemodialysis; M = male. a We found 19 previously reported cases. We did not include polymethylmethacrylate or paraffinoma cases. We found one case of death due to urinary sepsis from renal failure.
are not curative. Ketoconazole and bisphosphonates have been used with variable success. Surgical excision of the silicone tends to be ineffective due to silicone migration into adjacent areas. In conclusion, silicone-induced granulomatous inflammation is a rare cause of calcitriol-mediated hypercalcemia, and the clinical manifestations may take years to manifest. The treatment of this disorder is difficult and often ineffective and aimed at controlling the hypercalciuria and hypercalcemia.
